Contrast Ultrasound Imaging for Identification of Early Responder Tumor Models to Anti-Angiogenic Therapy
Ultrasound in Medicine and Biology, 04/09/2012Sirsi SR et al.
The authors conclude that the response to bevacizumab (BV) can be identified soon after initiation of treatment, often within 3 days, by use of contrast–enhanced ultrasound imaging (CEUS) molecular imaging techniques. The use of a noninvasive ultrasound approach may allow for earlier and more effective determination of efficacy of antiangiogenic therapy.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.